StockNews.com downgraded shares of MiMedx Group (NASDAQ:MDXG – Free Report) from a strong-buy rating to a buy rating in a report released on Friday morning.
A number of other research firms have also recently commented on MDXG. Cantor Fitzgerald reissued an “overweight” rating and issued a $11.00 price target on shares of MiMedx Group in a research note on Thursday, August 1st. Craig Hallum decreased their target price on shares of MiMedx Group from $14.00 to $12.00 and set a “buy” rating on the stock in a research report on Thursday, August 1st. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $12.00.
Read Our Latest Research Report on MDXG
MiMedx Group Trading Up 1.2 %
Hedge Funds Weigh In On MiMedx Group
Several institutional investors have recently bought and sold shares of MDXG. Headlands Technologies LLC bought a new position in shares of MiMedx Group in the 1st quarter worth approximately $27,000. Russell Investments Group Ltd. grew its holdings in shares of MiMedx Group by 5.0% during the 1st quarter. Russell Investments Group Ltd. now owns 551,546 shares of the company’s stock worth $4,247,000 after purchasing an additional 26,487 shares during the period. Isthmus Partners LLC boosted its position in MiMedx Group by 39.4% during the 1st quarter. Isthmus Partners LLC now owns 301,500 shares of the company’s stock valued at $2,322,000 after purchasing an additional 85,289 shares during the period. ProShare Advisors LLC grew its position in MiMedx Group by 8.5% during the 1st quarter. ProShare Advisors LLC now owns 20,735 shares of the company’s stock worth $160,000 after purchasing an additional 1,631 shares in the last quarter. Finally, Entropy Technologies LP acquired a new position in shares of MiMedx Group during the 1st quarter worth about $99,000. Institutional investors own 79.15% of the company’s stock.
About MiMedx Group
MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins.
Recommended Stories
- Five stocks we like better than MiMedx Group
- NYSE Stocks Give Investors a Variety of Quality Options
- Airbnb Stock Attracts Attention With Strong Cash Flow Strategy
- How to Invest in the FAANG Stocks
- MarketBeat Week in Review – 11/4 – 11/8
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- Trump’s Return: Which Sectors Will Benefit Most?
Receive News & Ratings for MiMedx Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MiMedx Group and related companies with MarketBeat.com's FREE daily email newsletter.